Drug intelligence / Profile preview

MOH-B2

Development stage: Preclinical
Lead developer: Multiomic Health
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MOH-B2 is a preclinical-stage therapeutic candidate being developed by Multiomic Health for the treatment of chronic kidney disease (CKD), specifically focusing on kidney inflammation and fibrosis across multiple etiologies. The program was identified using Multiomic Health's proprietary precision medicine platform, which leverages multi-omics data from patient biobanks to identify novel disease drivers. Multiomic Health has partnered with Alloy Therapeutics to utilize their antibody discovery platforms to develop monoclonal antibodies against the targets identified for the MOH-B2 program.

Beyond the preview

Go deeper on MOH-B2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOH-B2.

Explore the full profile